HIF-1α及CD31促进晚期肝癌转移及侵袭的分子机制
Molecular Mechanism of HIF-1α and CD31 Promoting Metastasis and Invasion of Advanced Hepatocellular Carcinoma
DOI: 10.12677/ACM.2022.121036, PDF,   
作者: 李 晗:滨州医学院第二临床医学院,山东 烟台;孔令群, 曹学峰:滨州医学院附属医院,山东 滨州;王学文:潍坊医学院附属医院,山东 潍坊;吴燕彬:平邑县人民医院,山东 平邑县;牛洪凯, 成 雨:滨州医学院烟台附属医院,山东 烟台
关键词: HIF-1αCD31肝癌上皮间充质转化(EMT)血管生成拟态(VM)转移侵袭HIF-1α CD31 Hepatocellular Carcinoma Epithelial-Mesenchymal Transition (EMT) Vasculogenic Mimicry (VM) Transfer Invasion
摘要: 缺氧是实体肿瘤微环境(TME)的重要生物学特征,与肿瘤的侵袭转移密切相关。由于正常组织的氧供无法为肿瘤细胞提供充足的生长条件,肿瘤细胞内部会加速新生血管的形成进一步加重缺氧。低氧诱导因子(HIF-1α)被认为是在低氧条件下激活的关键转录调节因子,相关研究表明HIF-1α在肝癌组织中呈高度表达,促进血管生成及肿瘤的侵袭和转移,并维持着肿瘤细胞的代谢,是肝细胞癌发生、发展过程中重要的调控蛋白之一,与HIF-1α相关的HCC治疗也取得了快速地进展。与此同时,研究发现TME可以通过血小板内皮细胞粘附因子1 (PECAM-1/CD31)发挥作用,推动晚期转移进展,并在肿瘤进展的前终末阶段中起关键作用,且HIF-1α与CD31表达具有相关性。本综述重点总结HIF-1α及CD31促进晚期肝癌(HCC)转移及侵袭的分子机制。
Abstract: Hypoxia is an important biological feature of solid tumor microenvironment (TME), which is closely related to tumor invasion and metastasis. As normal tissue oxygen supply cannot provide sufficient growth conditions for tumor cells, the formation of new blood vessels will be accelerated inside tumor cells to further aggravate hypoxia. HIF-1α is considered under the condition of low oxygen activation key transcriptional regulation factor. Related studies have shown that HIF-1α is highly expressed in liver cancer tissue, promotes angiogenesis and tumor invasion and metastasis, and maintains the tumor cell’s metabolism, which is one of the important regulatory proteins in the occurrence and development of hepatocellular carcinoma. HIF-1α-related HCC treatment has also made rapid progress. At the same time, TME was found to play a role through platelet endothelial cell adhesion factor 1 (PECAM-1/CD31), promoting the progression of late metastasis and playing a key role in the preterminal stage of tumor progression, and hiF-1α was correlated with CD31 expression. This review focuses on the molecular mechanisms by which HIF-1α and CD31 promote metastasis and invasion of advanced hepatocellular carcinoma (HCC).
文章引用:李晗, 孔令群, 曹学峰, 王学文, 吴燕彬, 牛洪凯, 成雨. HIF-1α及CD31促进晚期肝癌转移及侵袭的分子机制[J]. 临床医学进展, 2022, 12(1): 236-245. https://doi.org/10.12677/ACM.2022.121036

参考文献

[1] Semenza, G.L. (2011) Oxygen Sensing, Homeostasis, and Disease. The New England Journal of Medicine, 365, 537-47. [Google Scholar] [CrossRef
[2] Topalian, S.L., et al. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. The New England Journal of Medicine, 366, 2443-2454.
[3] Herbst, R.S., et al. (2014) Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature, 515, 563-567. [Google Scholar] [CrossRef] [PubMed]
[4] Gao, Q., et al. (2009) Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. Clinical Cancer Research, 15, 971-979. [Google Scholar] [CrossRef
[5] Calderaro, J., et al. (2016) Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship with Clinical and Pathological Features. Hepatology, 64, 2038-2046.
[6] DeLisser, H., et al. (2010) Vascular Endothelial Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1) Regulates Advanced Metastatic Progression. Proceedings of the National Academy of Sciences of the United States of America, 107, 18616-18621. [Google Scholar] [CrossRef] [PubMed]
[7] (2020) Erratum: Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 70, 313. [Google Scholar] [CrossRef] [PubMed]
[8] 王奕鸿, 方永平, 李坤平. 手术治疗余肝体积不足肝癌的研究进展[J]. 临床医学研究与实践, 2021(6): 190-192.
[9] Tanaka, M., et al. (2011) Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures. Journal of Epidemiology, 21, 401-416. [Google Scholar] [CrossRef
[10] Postow, M.A., Callahan, M.K. and Wolchok, J.D. (2015) Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology, 33, 1974-1982. [Google Scholar] [CrossRef
[11] Cockman, M.E., et al. (2000) Hypoxia Inducible Factor-Alpha Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein. Journal of Biological Chemistry, 275, 25733-25741. [Google Scholar] [CrossRef
[12] Jaakkola, P., et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation. Science, 292, 468-472. [Google Scholar] [CrossRef] [PubMed]
[13] Maxwell, P.H., et al. (1999) The Tumour Suppressor Protein VHL Targets Hypoxia-Inducible Factors for Oxygen-Dependent Proteolysis. Nature, 399, 271-275. [Google Scholar] [CrossRef] [PubMed]
[14] Greer, S.N., Metcalf, J.L., Wang, Y. and Ohh, M. (2012) The Updated Biology of Hypoxia-Inducible Factor. The EMBO Journal, 31, 2448-2460. [Google Scholar] [CrossRef] [PubMed]
[15] Shen, C. and Kaelin Jr., W.G. (2013) The VHL/HIF Axis in Clear Cell Renal Carcinoma. Seminars in Cancer Biology, 23, 18-25. [Google Scholar] [CrossRef] [PubMed]
[16] Xia, X., et al. (2009) Integrative Analysis of HIF Binding and Transactivation Reveals Its Role in Maintaining Histone Methylation Homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 106, 4260-4265. [Google Scholar] [CrossRef] [PubMed]
[17] Thienpont, B., et al. (2016) Tumour Hypoxia Causes DNA Hypermethylation by Reducing TET Activity. Nature, 537, 63-68. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, C., et al. (2001) Regulation of glut1 mRNA by Hypoxia-Inducible Factor-1. Interaction between H-ras and Hypoxia. Journal of Biological Chemistry, 276, 9519-9525. [Google Scholar] [CrossRef
[19] Amann, T., et al. (2009) GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis. The American Journal of Pathology, 174, 1544-1552. [Google Scholar] [CrossRef] [PubMed]
[20] Gwak, G.Y., et al. (2005) Hypoxia Stimulates Proliferation of Human Hepatoma Cells through the Induction of Hexokinase II Expression. Journal of Hepatology, 42, 358-364. [Google Scholar] [CrossRef] [PubMed]
[21] Semenza, G.L., et al. (1996) Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-Inducible Factor 1. Journal of Biological Chemistry, 271, 32529-32537. [Google Scholar] [CrossRef] [PubMed]
[22] Kim, J.W., et al. (2006) HIF-1-Mediated Expression of Pyruvate Dehydrogenase Kinase: A Metabolic Switch Required for Cellular Adaptation to Hypoxia. Cell Metabolism, 3, 177-185. [Google Scholar] [CrossRef] [PubMed]
[23] Lai, R.K., et al. (2016) NDUFA4L2 Fine-Tunes Oxidative Stress in Hepatocellular Carcinoma. Clinical Cancer Research, 22, 3105-3117. [Google Scholar] [CrossRef
[24] Masson, N. and Ratcliffe, P.J. (2014) Hypoxia Signaling Pathways in Cancer Metabolism: The Importance of Co-Selecting Interconnected Physiological Pathways. Cancer & Metabolism, 2, 3. [Google Scholar] [CrossRef] [PubMed]
[25] Zhang, L., et al. (2013) Hypoxia Induces Epithelial-Mesenchymal Transition via Activation of SNAI1 by Hypoxia-Inducible Factor-1α in Hepatocellular Carcinoma. BMC Cancer, 13, 108. [Google Scholar] [CrossRef] [PubMed]
[26] Copple, B.L. (2010) Hypoxia Stimulates Hepatocyte Epithelial to Mesenchymal Transition by Hypoxia-Inducible Factor and Transforming Growth Factor-Beta-Dependent Mechanisms. Liver International, 30, 669-682. [Google Scholar] [CrossRef] [PubMed]
[27] Tabatabai, G., et al. (2006) Irradiation and Hypoxia Promote Homing of Haematopoietic Progenitor Cells towards Gliomas by TGF-Beta-Dependent HIF-1alpha-Mediated Induction of CXCL12. Brain, 129, 2426-2435. [Google Scholar] [CrossRef] [PubMed]
[28] McMahon, S., et al. (2006) Transforming Growth Factor beta1 Induces Hypoxia-Inducible Factor-1 Stabilization through Selective Inhibition of PHD2 Expression. Journal of Biological Chemistry, 281, 24171-24181. [Google Scholar] [CrossRef
[29] Sahlgren, C., et al. (2008) Notch Signaling Mediates Hypoxia-Induced Tumor Cell Migration and Invasion. Proceedings of the National Academy of Sciences of the United States of America, 105, 6392-6397. [Google Scholar] [CrossRef] [PubMed]
[30] Tirpe, A.A., et al. (2019) Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes. International Journal of Molecular Sciences, 20, 6140. [Google Scholar] [CrossRef] [PubMed]
[31] Zhang, L., Liu, H.J., Mu, X.D., Cui, J.L. and Peng, Z.G. (2017) Dysregulation of Fra1 Expression by Wnt/β-Catenin Signalling Promotes Glioma Aggressiveness through Epithelial-Mesenchymal Transition. Bioscience Reports, 37, BSR20160643. [Google Scholar] [CrossRef
[32] Chen, Z., et al. (2018) MiR-3662 Suppresses Hepatocellular Carcinoma Growth through Inhibition of HIF-1α-Mediated Warburg Effect. Cell Death & Disease, 9, 549. [Google Scholar] [CrossRef] [PubMed]
[33] Li, B., et al. (2017) Mutual Regulation of MiR-199a-5p and HIF-1α Modulates the Warburg Effect in Hepatocellular Carcinoma. Journal of Cancer, 8, 940-949. [Google Scholar] [CrossRef] [PubMed]
[34] Zhang, L.F., et al. (2015) Suppression of miR-199a Maturation by HuR Is Crucial for Hypoxia-Induced Glycolytic Switch in Hepatocellular Carcinoma. The EMBO Journal, 34, 2671-2685. [Google Scholar] [CrossRef] [PubMed]
[35] Jiang, Y., et al. (2015) Temporal Regulation of HIF-1 and NF-κB in Hypoxic Hepatocarcinoma Cells. Oncotarget, 6, 9409-9419. [Google Scholar] [CrossRef] [PubMed]
[36] Xu, H., et al. (2014) MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1α. PLoS ONE, 9, e115565. [Google Scholar] [CrossRef] [PubMed]
[37] Csak, T., et al. (2015) microRNA-122 Regulates Hypoxia-Inducible Factor-1 and Vimentin in Hepatocytes and Correlates with Fibrosis in Diet-Induced Steatohepatitis. Liver International, 35, 532-541. [Google Scholar] [CrossRef] [PubMed]
[38] Chang, R.M., et al. (2016) MicroRNA-130b Promotes Proliferation and EMT-Induced Metastasis via PTEN/p-AKT/HIF-1α Signaling. Tumor Biology, 37, 10609-10619. [Google Scholar] [CrossRef] [PubMed]
[39] Lin, J., et al. (2018) Long Non-Coding RNA UBE2CP3 Enhances HCC Cell Secretion of VEGFA and Promotes Angiogenesis by Activating ERK1/2/HIF-1α/VEGFA Signalling in Hepatocellular Carcinoma. Journal of Experimental & Clinical Cancer Research, 37, 113. [Google Scholar] [CrossRef] [PubMed]
[40] Sun, T., et al. (2010) Expression and Functional Significance of Twist1 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry. Hepatology, 51, 545-556. [Google Scholar] [CrossRef] [PubMed]
[41] Wang, L., et al. (2015) Metastasis-Associated in Colon Cancer-1 Promotes Vasculogenic Mimicry in Gastric Cancer by Upregulating TWIST1/2. Oncotarget, 6, 11492-11506. [Google Scholar] [CrossRef] [PubMed]
[42] Chaw, S.Y., et al. (2012) Epithelial to Mesenchymal Transition (EMT) Biomarkers—E-Cadherin, Beta-Catenin, APC and Vimentin—in Oral Squamous Cell Carcinogenesis and Transformation. Oral Oncology, 48, 997-1006. [Google Scholar] [CrossRef] [PubMed]
[43] Xu, Y., et al. (2012) Short-Term Anti-Vascular Endothelial Growth Factor Treatment Elicits Vasculogenic Mimicry Formation of Tumors to Accelerate Metastasis. Journal of Experimental & Clinical Cancer Research, 31, 16. [Google Scholar] [CrossRef
[44] Wang, M., et al. (2017) HIF-1α Promoted Vasculogenic Mimicry Formation in Hepatocellular Carcinoma through LOXL2 Up-Regulation in Hypoxic Tumor Microenvironment. Journal of Experimental & Clinical Cancer Research, 36, 60. [Google Scholar] [CrossRef] [PubMed]
[45] Yang, J., et al. (2017) HIF-2α Promotes the Formation of Vasculogenic Mimicry in Pancreatic Cancer by Regulating the Binding of Twist1 to the VE-cadherin Promoter. Oncotarget, 8, 47801-47815. [Google Scholar] [CrossRef] [PubMed]
[46] Jiang, B. (2017) Aerobic Glycolysis and High Level of Lactate in Cancer Metabolism and Microenvironment. Genes and Diseases, 4, 25-27. [Google Scholar] [CrossRef] [PubMed]
[47] Chiche, J., Brahimi-Horn, M.C. and Pouysségur, J. (2010) Tumour Hypoxia Induces a Metabolic Shift Causing Acidosis: A Common Feature in Cancer. Journal of Cellular and Molecular Medicine, 14, 771-794. [Google Scholar] [CrossRef] [PubMed]
[48] Pouysségur, J., Dayan, F. and Mazure, N.M. (2006) Hypoxia Signalling in Cancer and Approaches to Enforce Tumour Regression. Nature, 441, 437-443. [Google Scholar] [CrossRef] [PubMed]
[49] Semenza, G.L. (2003) Targeting HIF-1 for Cancer Therapy. Nature Reviews Cancer, 3, 721-732. [Google Scholar] [CrossRef] [PubMed]
[50] Li, X.F., et al. (2007) Visualization of Hypoxia in Microscopic Tumors by Immunofluorescent Microscopy. Cancer Research, 67, 7646-7653. [Google Scholar] [CrossRef
[51] Li, X.F. and O’Donoghue, J.A. (2008) Hypoxia in Microscopic Tumors. Cancer Letters, 264, 172-180. [Google Scholar] [CrossRef] [PubMed]
[52] Cao, Y., et al. (2005) Observation of Incipient Tumor Angiogenesis That Is Independent of Hypoxia and Hypoxia Inducible Factor-1 Activation. Cancer Research, 65, 5498-5505. [Google Scholar] [CrossRef
[53] Yakata, Y., et al. (2007) Expression of p-STAT3 in Human Gastric Carcinoma: Significant Correlation in Tumour Invasion and Prognosis. International Journal of Oncology, 30, 437-442.
[54] Song, Y.Y., et al. (2014) STAT3, p-STAT3 and HIF-1α Are Associated with Vasculogenic Mimicry and Impact on Survival in Gastric Adenocarcinoma. Oncology Letters, 8, 431-437. [Google Scholar] [CrossRef] [PubMed]
[55] Xu, Q., et al. (2005) Targeting Stat3 Blocks both HIF-1 and VEGF Expression Induced by Multiple Oncogenic Growth Signaling Pathways. Oncogene, 24, 5552-5560. [Google Scholar] [CrossRef] [PubMed]
[56] Li, S., Meng, W., Guan, Z.W., Guo, Y.L. and Han, X.Z. (2016) The Hypoxia-Related Signaling Pathways of Vasculogenic Mimicry in Tumor Treatment. Biomedicine & Pharmacotherapy, 80, 127-135. [Google Scholar] [CrossRef] [PubMed]
[57] Zhang, J.G., et al. (2020) Hypoxic Induction of Vasculogenic Mimicry in Hepatocellular Carcinoma: Role of HIF-1 α, RhoA/ROCK and Rac1/PAK Signaling. BMC Cancer, 20, Article No. 32. [Google Scholar] [CrossRef] [PubMed]
[58] Fernández-Barral, A., et al. (2012) Hypoxia Negatively Regulates Antimetastatic PEDF in Melanoma Cells by a Hypoxia Inducible Factor-Independent, Autophagy Dependent Mechanism. PLoS ONE, 7, e32989. [Google Scholar] [CrossRef] [PubMed]
[59] Gustafsson, M.V., et al. (2005) Hypoxia Requires Notch Signaling to Maintain the Undifferentiated Cell State. Developmental Cell, 9, 617-628. [Google Scholar] [CrossRef] [PubMed]
[60] Quail, D.F., et al. (2011) Low Oxygen Levels Induce the Expression of the Embryonic Morphogen Nodal. Molecular Biology of the Cell, 22, 4809-4821. [Google Scholar] [CrossRef] [PubMed]
[61] Li, W., Zong, S.Q., Shi, Q., Li, H.J., Xu, J. and Hou, F.G. (2016) Hypoxia-Induced Vasculogenic Mimicry Formation in Human Colorectal Cancer Cells: Involvement of HIF-1a, Claudin-4, and E-Cadherin and Vimentin. Scientific Reports, 6, Article No. 37534. [Google Scholar] [CrossRef] [PubMed]
[62] Sun, J., et al. (2000) Contributions of the Extracellular and Cytoplasmic Domains of Platelet-Endothelial Cell Adhesion Molecule-1 (PECAM-1/CD31) in Regulating Cell-Cell Localization. Journal of Cell Science, 113, 1459-1469. [Google Scholar] [CrossRef] [PubMed]
[63] Newman, D.K., et al. (2002) Nitration of PECAM-1 ITIM Tyrosines Abrogates Phosphorylation and SHP-2 Binding. Biochemical and Biophysical Research Communications, 296, 1171-1179. [Google Scholar] [CrossRef
[64] Righi, L., et al. (2003) Role of CD31/Platelet Endothelial Cell Adhesion Molecule-1 Expression in in Vitro and in Vivo Growth and Differentiation of Human Breast Cancer Cells. The American Journal of Pathology, 162, 1163-1174. [Google Scholar] [CrossRef
[65] Sapino, A., et al. (2001) Expression of CD31 by Cells of Extensive Ductal in Situ and Invasive Carcinomas of the Breast. The Journal of Pathology, 194, 254-261. [Google Scholar] [CrossRef
[66] Stacchini, A., et al. (2003) Expression of the CD31 Antigen in Normal B-Cells and Non Hodgkin’s Lymphomas. Journal of Biological Regulators and Homeostatic Agents, 17, 308-315.
[67] Goldberger, A., Middleton, K.A. and Newman, P.J. (1994) Changes in Expression of the Cell Adhesion Molecule PECAM-1 (CD31) during Differentiation of Human Leukemic Cell Lines. Tissue Antigen, 44, 285-293. [Google Scholar] [CrossRef] [PubMed]
[68] Tang, D.G., et al. (1993) Identification of PECAM-1 in Solid Tumor Cells and Its Potential Involvement in Tumor Cell Adhesion to Endothelium. Journal of Biological Chemistry, 268, 22883-22894. [Google Scholar] [CrossRef
[69] Handra-Luca, A. (2019) CD31 Immunohistochemical Expression in Tumors. Applied Immunohistochemistry & Molecular Morphology, 27, e98-e99. [Google Scholar] [CrossRef
[70] Newman, P.J. and Newman, D.K. (2003) Signal Transduction Pathways Mediated by PECAM-1: New Roles for an Old Molecule in Platelet and Vascular Cell Biology. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 953-964. [Google Scholar] [CrossRef
[71] Ilan, N. and Madri, J.A. (2003) PECAM-1: Old Friend, New Partners. Current Opinion in Cell Biology, 15, 515-524. [Google Scholar] [CrossRef
[72] Jackson, D.E. (2003) The Unfolding Tale of PECAM-1. FEBS Letters, 540, 7-14. [Google Scholar] [CrossRef
[73] Abraham, V., et al. (2018) Involvement of TIMP-1 in PECAM-1-Mediated Tumor Dissemination. International Journal of Oncology, 53, 488-502. [Google Scholar] [CrossRef] [PubMed]
[74] Zhang, Y.Y., et al. (2018) CD31 Regulates Metastasis by Inducing Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma via the ITGB1-FAK-Akt Signaling Pathway. Cancer Letters, 429, 29-40. [Google Scholar] [CrossRef] [PubMed]
[75] Musumeci, G., et al. (2015) Enhanced Expression of CD31/Platelet Endothelial Cell Adhesion Molecule 1 (PECAM1) Correlates with Hypoxia Inducible Factor-1 Alpha (HIF-1α) in Human Glioblastoma Multiforme. Experimental Cell Research, 339, 407-416. [Google Scholar] [CrossRef] [PubMed]